Precision Biosensor KRX:335810KOSDAQ
프리시젼바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked3since Sep 11
In Q2 2026, Precision Biosensor reported revenue of ₩6.2bn, up 26.9% year on year, and an operating loss of ₩1.2bn. Precision Biosensor (프리시젼바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Precision Biosensor quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩6.2bn | +26.9% | −₩1.2bn margin −19.5% | −₩1.2bn |
| Q1 2026 | ₩7.0bn | +52.2% | ₩17m margin 0.2% | ₩133m |
| Q4 2025 derived | ₩5.3bn | +3.7% | −₩1.4bn margin −26.4% | −₩3.8bn |
| Q3 2025 | ₩5.1bn | +7.9% | −₩1.0bn margin −20.1% | −₩1.5bn |
| Q2 2025 | ₩4.9bn | -4.4% | −₩1.5bn margin −29.6% | −₩2.7bn |
| Q1 2025 | ₩4.6bn | +10.9% | −₩1.5bn margin −32.6% | −₩2.0bn |
| Q4 2024 derived | ₩5.1bn | +22.0% | −₩913m margin −17.9% | −₩1.6bn |
| Q3 2024 | ₩4.7bn | +29.5% | −₩1.3bn margin −27.2% | −₩2.6bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Precision Biosensor top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.